Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.36 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL10994135 | 0.97 | ALDH1A1 (0.78) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL5590823 | 0.97 | ALDH1A1 (0.78) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL28062101 | 0.95 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL28062099 | 0.95 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL9007287 | 0.92 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL27313732 | 0.90 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL940072 | 0.89 | — | — | |
| Ethyl Acetate SCHEMBL29260857 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL11423347 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL28902693 | 0.87 | ALDH1A1 (0.70) | ALDH1A1LMNAHSD17B10TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119430965-A | Anti-erosion castable for waste alkali liquid incinerator and preparation method thereof | 宜兴瑞泰耐火材料有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-108484687-A | The preparation method of technetium-99 m labeled triphenylphosphine salt derivative and application | 河南中医药大学 | 2018-09-04 | — | — | CN | claimed |
| CN-103086937-A | Method for synthesizing paricalcitol | SHANGHAI PUYI CHEMICAL TECHNOLOGY CO LTD | 2013-05-08 | — | — | CN | claimed |
| CN-119430965-A | Anti-erosion castable for waste alkali liquid incinerator and preparation method thereof | 宜兴瑞泰耐火材料有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250049968-A1 | THERAPEUTIC AND IMAGING AGENTS FOR TARGETING MYOCARDIAL TISSUE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-02-13 | — | — | US | disclosed |
| CN-118108791-A | Synthetic method of Boc-Tyr (tBu) -Aib-Glu (OtBu) -Gly-OH | 成都普康唯新生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023205291-A2 | TARGETING MYOCARDIAL TISSUE FOR DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-107108631-B | 6-amino-7-bicyclic-7-deaza-purine derivatives as protein kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2020-06-16 | — | — | CN | disclosed |
| CN-110498757-A | A kind of synthetic method for the 3- acyl indol class compound that no metal participates in | LANZHOU INST CHEMICAL PHYSICS CAS | 2019-11-26 | — | — | CN | disclosed |
| CN-110431454-A | Phase difference film, multilayer phase difference film, polarizing film, image display device and polymerizable compound | ZEON CORP | 2019-11-08 | — | — | CN | disclosed |
| CN-110382514-A | Prodrugs of HCV NS5B polymerase inhibitors and methods of making and using the same | 亚历山大·瓦西里耶维奇·伊瓦切恩科 | 2019-10-25 | — | — | CN | disclosed |
| CN-1147250-A | Naphthalene derivs. as prostaglandin I2 agonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-04-09 | — | — | CN | disclosed |
| CN-1033750-C | Intermediate compounds for the preparation of aromatic amino alcohol derivatives having anti-diabetic and anti-obesity properties | SANKYO CO (JP) | 1997-01-08 | — | — | CN | disclosed |
| CN-1132505-A | Amidine derivatives with nitric oxide synthetase activities | ASTERA CO (SE) | 1996-10-02 | — | — | CN | disclosed |
| CN-1106396-A | Intermediate compounds for the preparation of aromatic amino alcohol derivatives having anti-diabetic and anti-obesity properties | SANKYO CO (JP) | 1995-08-09 | — | — | CN | disclosed |
| CN-1075141-A | 1,4-dihydropyridine-3, the preparation of 5-dicarboxylic acid esters and purposes | BAYER AG (DE) | 1993-08-11 | — | — | CN | disclosed |
| CN-1073428-A | Aromatic amino alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic use | SANKYO CO (JP) | 1993-06-23 | — | — | CN | disclosed |
| CN-1015057-B | process for preparation of piperazinyl-heterocyclic compounds | PFIZER (US) | 1991-12-11 | — | — | CN | disclosed |
| CN-88101642-A | Piperazinyl-heterogeneous ring compound | — | 1988-09-14 | — | — | CN | disclosed |
| CN-85107088-A | The preparation of the heterocyclic immunostimulants that peptide replaces | — | 1986-06-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049968-A1 | THERAPEUTIC AND IMAGING AGENTS FOR TARGETING MYOCARDIAL TISSUE | MYLK2, MYOF, MYL6 | CHRM1 507/4885CHRM3 334/4885CHRM2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.